NCT05761509已完成不适用
"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba3 个研究点 分布在 1 个国家目标入组 226 人开始时间: 2023年6月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 226
- 试验地点
- 3
- 主要终点
- To assess the adherence of post exposure prophylaxis treatment with doravirine (using Delstrigo® or Pifeltro®), prescribed to subjects exposed to HIV according to French national recommendations.
研究概览
简要总结
The main objective of this observational study is to assess the adherence of post exposure prophylaxis treatment with doravirine (using Delstrigo® or Pifeltro®), prescribed to subjects exposed to HIV according to French national recommendations.
This study will evaluate:
- the percentage of subjects who followed their treatment within the prescribed 28 days,
- the prevalence and type of side effects in subjects on this treatment,
- the occurrence of HIV seroconversion associated with this combination.
详细描述
The study visits are those routinely performed in the standard care of the subjects using PEP and are the following:
Visit 1 (between day 1 to day 8 after PEP treatment initiation):
- Subject information and inclusion in the study,
- Pregnancy test (urine or serum) for women of childbearing potential (WOCBP)
- Delivery of a follow-up subject diary (daily information about PEP treatment intake, concomitant treatments and potential side effects/adverse events)
Visit 2 (From 42 days to 90 days after PEP treatment initiation)
- Treatment observance (PEP),
- Return of the follow-up subject diary,
- Check of the follow-up subject diary completion,
- Keep a copy of the HIV serology and/or viral load results in the medical file.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age more than 18 years old
- •Exposure to HIV, leading to the prescription of 28-day post exposure prophylaxis (PEP)
- •PEP with doravirine:
- •Delstrigo® (tenofovir disoproxil, doravirine, lamivudine),
- •Or Pifeltro® (doravirine) in association with tenofovir disoproxil/emtricitabine.
- •Participant who can understand, read and speak French.
- •With or without health insurance.
- •Cisgender female and Female to Male transgender participants are eligible to participate if they are not pregnant or breastfeeding, and at least one of the following conditions applies: •
- •Is not a WOCBP (Women Of Childbearing Potential) OR
- •Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), or be abstinent as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the treatment period and for at least 8 weeks after the last dose. The investigator should evaluate the potential for contraceptive method failure (i.e., non compliance, recently initiated) in relationship to the first dose of PEP treatment.
- •A WOCBP must have a negative pregnancy test (urine or serum) before inclusion in the study. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant should not be included in the study if the serum pregnancy result is positive.
排除标准
- •Contraindication to Delstrigo® or Pifeltro® or tenofovir disoproxil/emtricitabine: hypersensitivity to active substances or excipients.
- •Contra-indicated treatment likely to interfere with the study drugs as listed in the summary of the product characteristics.
- •Viral resistance of the source subject known and unsuitable for the prescription of doravirine
- •Simultaneous participation in another clinical trial with an experimental treatment or any intervention, which may have impact/change onto the PEP treatments or within an exclusion period of a previous clinical trial at screening.
- •Subjects under legal guardianship or unable to express their consent.
- •Subject privated of liberty by judicial or administrative decision or subject under psychiatric care or admitted to a health or social establishment.
研究组 & 干预措施
Single arm
200 subjects exposed to HIV, leading to prescription of 28-day doravirine based post exposure prophylaxis (PEP).
The study referred to treatments that are using routinely in the medical care of subjects under PEP. These treatments are the following:
- Delstrigo®: Fixed-dose combination containing 100mg of doravirine, 245 mg of tenofovir disoproxil and 300 mg of lamivudine, one tablet to be taken orally once daily, with or without food.
- Pifeltro®: doravirine dosed at 100 mg, on tablet to be taken orally once daily, with or without food, in combination with tenofovir disoproxil/emtricitabine.
干预措施: Doravirine (Drug)
结局指标
主要结局
To assess the adherence of post exposure prophylaxis treatment with doravirine (using Delstrigo® or Pifeltro®), prescribed to subjects exposed to HIV according to French national recommendations.
时间窗: 3 months
Proportion of subjects who complete the total period of treatment (intake during 28 days). The treatment completeness will be defined as follows: * no missing treatment intake from D1 to D14, * and no more than 2 missing treatment intakes from D15 to D28.
次要结局
- To evaluate the tolerability of PEP with doravirine.(28 days)
- To evaluate the prevalence of HIV seroconversion associated with this combination.(3 months)
- To compare the adherence of post exposure prophylaxis treatment between Delstrigo® or Pifeltro®(28 days)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)Multiple System AtrophyNCT04495582Corestemchemon, Inc.8
已完成
4 期
Post-Exposure Prophylaxis in Health Care WorkersHuman Immunodeficiency VirusNCT01234116Henry Ford Health System16
已完成
不适用
Adherence to Secondary Prevention Guidelines for Cardiovascular RiskAtherosclerosisStroke, IschemicIschemic Heart DiseaseAcute Coronary SyndromePeripheral Arterial DiseaseNCT06450561Consorci Sanitari de l'Alt Penedès i Garraf129
已完成
不适用
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer PatientsBreakthrough Cancer PainNCT03895762A.Menarini Asia-Pacific Holdings Pte Ltd143
Enrolling By Invitation
不适用
A Long Term Follow-Up Study for Subjects Who Have Received Q-CellsTransverse MyelitisNCT06163508University of Texas Southwestern Medical Center9